Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exploring P-glycoprotein-mediated efflux transport at the blood-brain barrier as a biomarker of drug-resistance in focal epilepsy
2019-003137-42Phase 2Active
- Sponsor
- Department of Clinical Pharmacology, Medical University of Vienna
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of metoclopramide in Focal Onset Epilepsy, sponsored by Department of Clinical Pharmacology, Medical University of Vienna. Primary endpoint: kE,brain elimination slope for radioactivity washout from the brain. Started Feb 2020; status: active.
02
Drugs
metoclopramide
03
Conditions
Focal Onset Epilepsy
Beyond the preview
Go deeper on 2019-003137-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003137-42.